Mar112020UncategorizedCategory: UncategorizedBy Charlotte Maddalena11 March 2020 Author: Charlotte Maddalena Post navigationPreviousPrevious post:First patient treated with anti-CD39 mAb IPH5201 on OREGA’s 10-year anniversary dayNextNext post:Three new projects supported by our FoundationRelated PostsORPHELIA Pharma has been awarded a € 1 million grant from Bpifrance to develop a therapy for a rare form of epilepsy11 May 2022No title28 April 2022Sondage sur notre communication12 April 2022Jeremy BASTID, CEO of OREGA Biotech, will participate to the upcoming AACR annual meeting to be held on April 9-13 in New Orleans, Louisiana4 April 2022International Childhood Cancer Day15 February 2022Two new projects supported by our Foundation7 February 2022
ORPHELIA Pharma has been awarded a € 1 million grant from Bpifrance to develop a therapy for a rare form of epilepsy11 May 2022
Jeremy BASTID, CEO of OREGA Biotech, will participate to the upcoming AACR annual meeting to be held on April 9-13 in New Orleans, Louisiana4 April 2022
